Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares dropped 3% during mid-day trading on Thursday . The company traded as low as $25.36 and last traded at $25.41, with a volume of 1,300,851 shares changing hands. The stock had previously closed at $26.19.

SRPT has been the subject of a number of analyst reports. Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating and set a $11.60 price objective for the company in a report on Wednesday, April 27th. Jefferies Group cut shares of Sarepta Therapeutics from a “hold” rating to an “underperform” rating and boosted their price target for the stock from $7.00 to $13.80 in a report on Friday, April 29th. Oppenheimer Holdings Inc. upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a report on Monday, May 2nd. They noted that the move was a valuation call. WBB Securities restated a “strong-buy” rating and set a $40.00 price target on shares of Sarepta Therapeutics in a report on Monday, May 2nd. Finally, Leerink Swann cut shares of Sarepta Therapeutics from a “market perform” rating to an “underperform” rating and cut their price target for the stock from $13.00 to $5.00 in a report on Monday, May 2nd. Five analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. Sarepta Therapeutics currently has an average rating of “Hold” and an average target price of $25.28.

The firm has a 50 day moving average price of $24.26 and a 200-day moving average price of $19.15. The stock’s market cap is $1.23 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period in the previous year, the business earned ($0.87) earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics Inc. will post ($5.16) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Sarepta Therapeutics stock. Jennison Associates LLC raised its position in Sarepta Therapeutics Inc. (NASDAQ:SRPT) by 463.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 838,629 shares of the company’s stock after buying an additional 689,831 shares during the period. Jennison Associates LLC owned 1.85% of Sarepta Therapeutics worth $32,354,000 as of its most recent filing with the SEC.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.